Long Acting Methylphenidate (Concertaâ„¢) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Long Acting Methylphenidate (Concertaâ„¢) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer.
PURPOSE: This randomized phase III trial is studying methylphenidate to see how well it works in treating patients with fatigue caused by cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to disease stage (0, I, or II vs III or IV), level of fatigue at baseline (4-7 vs 8-10), concurrent biological therapy (yes vs no), concurrent chemotherapy (yes vs no), and concurrent radiotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
Patients in both arms complete questionnaires to assess their symptoms of fatigue, overall mood, quality of life, sleep quality, and adverse effects from treatment at baseline and once weekly for 4 weeks. Patients also complete a Symptom Experience Diary.
McNeil Consumer & Specialty Pharmaceuticals provided medication support for NCCTG N05C7.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Inclusion Criteria:
≥ 18 years of age
Men or women with a history of cancer-related fatigue as defined by a score ≥ 4 on a fatigue numerical analogue scale (0 - 10)
Fatigue for ≥ 1 month prior to registration
ECOG Performance Score (PS) 0, 1, or 2
Life expectancy ≥ 6 months
Histologic or cytologic proven cancer other than brain cancer or CNS lymphoma
Laboratory values obtained ≤ 30 days prior to registration:
Willing and able to provide informed consent
Negative pregnancy test (urine or serum) done ≤ 7 days prior to registration, for women of childbearing potential only
Ability to complete questionnaire(s) by themselves or with assistance
Biological therapy (i.e. immunotherapy, biotherapy), chemotherapy or radiation therapy will be allowed
Use of a stable dose of anti-depressants (except tricyclic anti-depressants) will be allowed
Erythropoietic agents to treat anemia, and steroids as a part of cancer treatment and for symptom management (except for fatigue) will be allowed
Exclusion Criteria:
Hypersensitivity to methylphenidate
Any prior use of methylphenidate
Concomitant (≤ 2 weeks) use of prescription stimulants (pemoline, modafinil, amphetamines); other medications, herbal products or dietary supplements for fatigue
Uncontrolled hypertension [defined as systolic blood pressure (BP) ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg on 2 separate visits ≤ 2 months prior to randomization]; or a resting heart rate > 100
Moderate or severe pain as defined by an average daily score ≥ 4 on a pain analog scale (0 - 10)
Known brain metastasis or primary CNS malignancy
Clinically significant acute or chronic progressive or unstable neurologic (dementia, delirium, or seizure disorder), hepatic, renal, cardiovascular, thyroid, or respiratory disease that would limit participation in the study per MD discretion or judgment
Psychiatric disorder such as manic depression, anxiety disorder, bipolar disorder, obsessive compulsive disorder, or schizophrenia
Major surgery < 4 weeks prior to registration. (Note: Insertion of central venous catheter is not considered major surgery.)
Using a drug contraindicated when taken concurrently with methylphenidate: coumarin anticoagulants, anticonvulsants, tricyclic antidepressants, antipsychotics, monoamine oxidase inhibitors, clonidine, theophylline, and pseudoephedrine
Note: use of Compazine prescribed as an antiemetic is permitted for use while participating in this study.
Additional medical conditions where use of methylphenidate is contraindicated:
glaucoma, motor tics, family history or diagnosis of Tourette's syndrome, history of drug or alcohol abuse or intestinal obstruction.
Pregnant women or nursing women. Women of childbearing potential who are unwilling to employ adequate contraception. This study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown.
Untreated hypothyroidism (TSH ≥ 5)
Grand Junction, Colorado 81502, United States
Moline, Illinois 61265, United States
Ottawa, Illinois 61350, United States
Peoria, Illinois 61615, United States
Beech Grove, Indiana 46107, United States
La Porte, Indiana 46350, United States
Des Moines, Iowa 50309, United States
Des Moines, Iowa 50314, United States
Wichita, Kansas 67214, United States
Dearborn, Michigan 48123-2500, United States
Grosse Pointe Woods, Michigan 48236, United States
Minneapolis, Minnesota 55407, United States
Robbinsdale, Minnesota 55422-2900, United States
Billings, Montana 59101, United States
Missoula, Montana 59807, United States
Portland, Oregon 97213-2967, United States
Portland, Oregon 97227, United States
Wilkes-Barre, Pennsylvania 18711, United States
Spartanburg, South Carolina 29303, United States
Sioux Falls, South Dakota 57117-5039, United States
Green Bay, Wisconsin 54301-3526, United States